This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Engert, A. Articles by Thorpe, P. Search for Related Content PubMed Articles by Engert, A. Articles by Thorpe, P.

Evaluation of Ricin A Chain-containing Immunotoxins Directed against the CD30 Antigen as Potential Reagents for the Treatment of Hodgkin's Disease¹

The Drug Targeting Laboratory, Imperial Cancer Research Fund, Lincoln's Inn Fields, London WC2A 3PX, United Kingdom; The Medizinische Universitaetsklinik I, Joseph-Stelzmannstrasse 9, 5000 Koeln 41, West Germany; and The Institut fuer Pathologie, Freie Universitaet Berlin, Hindenburgdamm 30, 1000 Berlin 45, West Germany

Five monoclonal CD30 antibodies and two Fab' fragments were linked to deglycosylated ricin A chain (dgA), and their potential as immunotoxins for the treatment of Hodgkin's disease was evaluated. Cross-blocking experiments demonstrated that HRS-1, HRS-3, HRS-4, and Ber-H2 recognize the same epitope on the CD30 antigen and that Ki-1 binds to a different epitope. Scatchard analyses showed that HRS-3, HRS-4, and Ber-H2 bound strongly to L540 Hodgkin cells (K_d 15,7, and 14 nM, respectively), whereas HRS-1 and Ki-1 bound more weakly (K_d 160 and 380 nM, respectively). The different affinities of the antibodies correlated closely with their cytotoxic potency as immunotoxins. HRS-3.dgA, HRS-4.dgA, and Ber-H2.dgA inhibited the protein synthesis of L540 cells by 50% at concentrations of 0.9–2.0 x 10^-10 M, whereas HRS-1.dgA and Ki-1.dgA were about 100 times less potent with 50% inhibitory concentrations of 0.8–1.0 x 10^-8 M. The most effective immunotoxins, HRS-3.dgA and HRS-4.dgA, were only 15 times less toxic than ricin itself. HRS-3 Fab'.dgA and HRS-4 Fab'.dgA were 7.8 and 3 times less potent than their IgG.dgA counterparts with 50% inhibitory concentrations of 7 x 10^-10 and 3 x 10^-10 M, respectively. Staining of human tissues revealed an unexpected cross-reactivity of HRS-4 with pancreatic cells of malignant and nonmalignant origin. HRS-1, HRS-3, Ber-H2, and Ki-1 showed very little cross-reactivity with any normal human tissues. It is concluded that HRS-3.dgA and HRS-3 Fab'.dgA are the immunotoxins of choice for in vivo therapy.

¹ This work was in part supported by the Deutsche Forschungsgemeinschaft Grant EN 179/1-1.

Received 6/26/89. Revised 9/25/89. Accepted 10/ 3/89.

This article has been cited by other articles:

				S. Nagata, T. Ise, M. Onda, K. Nakamura, M. Ho, A. Raubitschek, and I. H. Pastan Cell membrane-specific epitopes on CD30: Potentially superior targets for immunotherapy PNAS, May 31, 2005; 102(22): 7946 - 7951. [Abstract] [Full Text] [PDF]

				P. Borchmann, J. F. Treml, H. Hansen, C. Gottstein, R. Schnell, O. Staak, H.-f. Zhang, T. Davis, T. Keler, V. Diehl, et al. The human anti-CD30 antibody 5F11 shows in vitro and in vivo activity against malignant lymphoma Blood, November 15, 2003; 102(10): 3737 - 3742. [Abstract] [Full Text] [PDF]

				P. Borchmann, R. Schnell, I. Fuss, O. Manzke, T. Davis, L. D. Lewis, D. Behnke, C. Wickenhauser, P. Schiller, V. Diehl, et al. Phase 1 trial of the novel bispecific molecule H22xKi-4 in patients with refractory Hodgkin lymphoma Blood, October 16, 2002; 100(9): 3101 - 3107. [Abstract] [Full Text] [PDF]

				M. Huhn, S. Sasse, M. K. Tur, B. Matthey, T. Schinkothe, S. M. Rybak, S. Barth, and A. Engert Human Angiogenin Fused to Human CD30 Ligand (Ang-CD30L) Exhibits Specific Cytotoxicity against CD30-positive Lymphoma Cancer Res., December 1, 2001; 61(24): 8737 - 8742. [Abstract] [Full Text] [PDF]

				S. Barth, M. Huhn, B. Matthey, S. Tawadros, R. Schnell, T. Schinkothe, V. Diehl, and A. Engert Ki-4(scFv)-ETA', a new recombinant anti-CD30 immunotoxin with highly specific cytotoxic activity against disseminated Hodgkin tumors in SCID mice Blood, June 15, 2000; 95(12): 3909 - 3914. [Abstract] [Full Text] [PDF]

				A. Engert, V. Diehl, R. Schnell, A. Radszuhn, M.-T. Hatwig, S. Drillich, G. Schon, H. Bohlen, H. Tesch, M.-L. Hansmann, et al. A Phase-I Study of an Anti-CD25 Ricin A-Chain Immunotoxin (RFT5-SMPT-dgA) in Patients With Refractory Hodgkin's Lymphoma Blood, January 15, 1997; 89(2): 403 - 410. [Abstract] [Full Text] [PDF]

				F. K. Stevenson Hodgkin's Disease -- New Insights from Immunoglobulin Genetics N. Engl. J. Med., October 5, 1995; 333(14): 934 - 936. [Full Text]